13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001799883
Total reported value
$287.9M
$287.9M
25 檔
40.6%
In Q3 2025, 5AM Venture Management, LLC's U.S. equity holdings reached a combined market value of $287.9M, distributed across 25 disclosed stock positions.
In Q3 2025, 5AM Venture Management, LLC adopted a defensive or profit-taking posture, trimming 5 positions and completely liquidating 7 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SKYE | Skye Bioscience Inc | Stock-Other | 13.94% | +0.68% | -2.33% | |
| 2 | TRDA | Entrada Therapeutics Inc | Stock-Other | 9.04% | -3.84% | -1.21% | |
| 3 | PHVS | Pharvaris N.V. | Stock-Other | 7.29% | +3.32% | — | |
| 4 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 6.45% | +1.72% | +100.45% | |
| 5 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 6.05% | -6.41% | EXIT | |
| 6 | VRDN | Viridian Therapeutics Inc | Stock-Other | 5.82% | — | — | |
| 7 | ELVN | Enliven Therapeutics Inc | Stock-Other | 5.79% | — | — | |
| 8 | EYPT | Eyepoint Inc | Stock-Other | 5.48% | +1.46% | — | |
| 9 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 5.26% | — | -62.93% | |
| 10 | TYRA | Tyra Biosciences Inc | Stock-Other | 4.81% | +0.48% | — | |
| 11 | CLDX | Celldex Therapeutics Inc | Stock-Other | 4.71% | +2.05% | — | |
| 12 | ERAS | Erasca Inc | Stock-Other | 4.32% | -15.66% | EXIT | |
| 13 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.30% | — | — | |
| 14 | GHRS | GH Research PLC | Stock-Other | 3.00% | -2.24% | EXIT | |
| 15 | TECX | Tectonic Therapeutic Inc | Stock-Other | 2.94% | +2.03% | — | |
| 16 | BHVN | Biohaven Ltd. | Stock-Other | 2.63% | +2.08% | — | |
| 17 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 2.47% | +3.72% | — | |
| 18 | SRZN | Surrozen Inc | Stock-Other | 1.46% | -0.69% | — | |
| 19 | TARA | Protara Therapeutic Inc | Stock-Other | 1.27% | -0.16% | — | |
| 20 | ALEC | Alector Inc | Stock-Other | 1.08% | — | — | |
| 21 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.91% | +1.12% | — | |
| 22 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.90% | — | — | |
| 23 | ✓ | Rallybio CORP | Stock-Other | 0.66% | — | — | |
| 24 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.27% | +4.09% | — | |
| 25 | MRSN | Mersana Therapeutics Inc | Stock-Other | 0.15% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SKYE | Skye Bioscience Inc | +8% | -2.33% | Trim |
| 2 | EYPT | Eyepoint Inc | +3.3% | — | Unchanged |
| 3 | PHVS | Pharvaris N.V. | +2.6% | — | Unchanged |
| 4 | VRDN | Viridian Therapeutics Inc | +2.1% | — | Unchanged |
| 5 | CAMP | Camp4 Therapeutics CORP | +2% | +100.45% | Add |
| 6 | 260 | Centessa Pharmaceuticals-adr | +1.5% | -18.05% | Trim |
| 7 | ERAS | Erasca Inc | +1.5% | — | Unchanged |
| 8 | TYRA | Tyra Biosciences Inc | +1.5% | — | Unchanged |
| 9 | CLDX | Celldex Therapeutics Inc | +1.3% | — | Unchanged |
| 10 | PRAX | Praxis Precision Medicines I | +0.9% | — | Unchanged |
| 11 | ALEC | Alector Inc | +0.6% | — | Unchanged |
| 12 | GHRS | GH Research PLC | +0.6% | — | Unchanged |
| 13 | SLN | Silence Therapeutics Plc-adr | +0.4% | — | Unchanged |
| 14 | SRZN | Surrozen Inc | +0.1% | — | Unchanged |
| 15 | AVU0 | Adverum Biotechnologies Inc | — | — | Unchanged |
| 16 | TARA | Protara Therapeutic Inc | 0% | — | Unchanged |
| 17 | ZNTL | Zentalis Pharmaceuticals Inc | 0% | — | Unchanged |
| 18 | ARTV | Artiva Biotherapeutics Inc | -0.2% | — | Unchanged |
| 19 | ✓ | Rallybio CORP | -0.2% | — | Unchanged |
| 20 | TECX | Tectonic Therapeutic Inc | -0.5% | — | Unchanged |
| 21 | BHVN | Biohaven Ltd. | -1.7% | — | Unchanged |
| 22 | DNTH | Dianthus Therapeutics Inc | -1.8% | -62.93% | Trim |
| 23 | ELVN | Enliven Therapeutics Inc | -4.1% | — | Trim |
| 24 | TRDA | Entrada Therapeutics Inc | -6% | -1.21% | Trim |
| 25 | MLTX | Moonlake Immunotherapeutics | — | EXIT | Sold out |
| 26 | ANAB | Anaptysbio Inc | — | EXIT | Sold out |
| 27 | VKTX | Viking Therapeutics Inc | — | EXIT | Sold out |
| 28 | VOR | Vor Biopharma Inc. | — | EXIT | Sold out |
| 29 | SCPH | Scpharmaceuticals Inc | — | EXIT | Sold out |
| 30 | CDTX | Cidara Therapeutics Inc | — | EXIT | Sold out |
| 31 | ✓ | Mersana Therapeutics Inc | — | EXIT | Sold out |
| 32 | MRSN | Mersana Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, 5AM Venture Management, LLC reported a total U.S. public equity portfolio value of $287.9M across 25 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SKYE, TRDA, PHVS) accounted for 40.6% of total reported equity market value during Q3 2025.
Top New Position Initiated
MRSN
市值: $405.1K
Top Position Liquidated / Trimmed
MLTX
前期市值: $11.0M
During Q3 2025, 5AM Venture Management, LLC's top holdings by market value included SKYE (13.9%)、TRDA (9.0%)、PHVS (7.3%). The largest single position, SKYE, represented 13.9% of total portfolio value.
In Q3 2025, 5AM Venture Management, LLC made 14 total portfolio adjustments, initiating 1 new buys, adding to 1 positions, trimming 5 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.